| human | Q5 |
| P6178 | Dimensions author ID | 0636314430.55 |
| P496 | ORCID iD | 0000-0002-9597-3010 |
| P69 | educated at | Hannover Medical School | Q911561 |
| National Institute of Pharmaceutical Education and Research, S.A.S. Nagar | Q3631392 | ||
| Punjabi University Department of Pharmaceutical Sciences and Drug Research | Q101004104 | ||
| P108 | employer | Hannover Medical School | Q911561 |
| Central Drug Research Institute | Q3633045 | ||
| BioNTech | Q30256699 | ||
| Universitätsklinikum Gießen und Marburg - Standort Marburg | Q101837221 | ||
| P734 | family name | Chaturvedi | Q4872271 |
| Chaturvedi | Q4872271 | ||
| Chaturvedi | Q4872271 | ||
| P106 | occupation | researcher | Q1650915 |
| Q52955493 | Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. |
| Q39023773 | All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase |
| Q42660724 | Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia |
| Q80223410 | Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model |
| Q28242368 | Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation |
| Q38981878 | Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling |
| Q41657181 | Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators |
| Q37632016 | Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate |
| Q46797127 | Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). |
| Q38511746 | Enigmas of IDH mutations in hematology/oncology |
| Q27313988 | Genetic deletion of SEPT7 reveals a cell type-specific role of septins in microtubule destabilization for the completion of cytokinesis |
| Q99572140 | IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis |
| Q36036304 | Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. |
| Q47755956 | Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. |
| Q45041099 | Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications |
| Q87247099 | Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation |
| Q45306545 | Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia |
| Q39749689 | Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes |
| Q38459847 | Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia |
| Q53757706 | Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. |
Search more.